Leap Therapeutics (NASDAQ:LPTX) Given Neutral Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Leap Therapeutics (NASDAQ:LPTX) in a research note issued to investors on Thursday morning,Benzinga reports.

Other research analysts have also issued reports about the stock. Baird R W lowered shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 29th. Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $9.00 to $1.25 in a research report on Wednesday, January 29th.

Leap Therapeutics Stock Performance

NASDAQ LPTX opened at $0.36 on Thursday. The business has a fifty day moving average price of $0.73 and a 200 day moving average price of $2.19. The company has a market cap of $13.98 million, a P/E ratio of -0.19 and a beta of 0.35. Leap Therapeutics has a one year low of $0.36 and a one year high of $4.79.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Wednesday, March 26th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. As a group, sell-side analysts predict that Leap Therapeutics will post -1.84 EPS for the current fiscal year.

Institutional Trading of Leap Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LPTX. Prosperity Wealth Management Inc. purchased a new position in shares of Leap Therapeutics during the 4th quarter worth $63,000. HighTower Advisors LLC acquired a new stake in shares of Leap Therapeutics in the third quarter valued at $65,000. Jane Street Group LLC purchased a new stake in shares of Leap Therapeutics in the 4th quarter valued at $107,000. Dauntless Investment Group LLC purchased a new stake in shares of Leap Therapeutics in the 4th quarter valued at $144,000. Finally, NewEdge Advisors LLC lifted its stake in Leap Therapeutics by 1,668,066.7% during the 4th quarter. NewEdge Advisors LLC now owns 50,045 shares of the company’s stock worth $144,000 after acquiring an additional 50,042 shares in the last quarter. Institutional investors and hedge funds own 30.46% of the company’s stock.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.